Box Inc vs Cassava Sciences Inc — how do they compare? Box Inc trades at $32.49 (market cap $4.55B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Box Inc is far larger — about 95.3× Cassava Sciences Inc's market cap, and Box Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| BOX | FLNA | |
|---|---|---|
Market Cap | $4.55B | $47.75M |
Sector | Technology | Health |
52-Week High | $33.60 | $4.64 |
52-Week Low | $21.37 | $0.87 |
Enterprise Value | $5.10B | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
BOX trades at $33.6, up 1.08% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income reaching $244.62M and a high gross margin of 79.56%. Recent news highlights Box's AI-ready content platform adoption, such as the Quintas Energy partnership announced on July 30, 2026.
The outlook is positive with a $37 consensus price target, but risks include a high P/E of 51.3 and competitive pressures. Earnings beat expectations in two of the last three quarters, supporting growth momentum, though valuation remains elevated relative to peers.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →